Skip to content

Study · Animal study (in vivo) · mouse · 2019

7 results

Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System.

Chiou HC, Lin MW, Hsiao PJ, Chen CL, Chiao S, Lin TY, Chen YC, Wu DC, Lin MH

International journal of molecular sciences29 Mar 2019Cited by 36 (Europe PMC)

PMID30934882 (opens in a new tab)PMCIDPMC6479396 (opens in a new tab)DOI10.3390/ijms20071584 (opens in a new tab)PepBankPUB-30934882
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

GLP-1 (glucagon-like peptide-1) has been reported to play a vital role in neuroprotection. Experimental autoimmune encephalomyelitis (EAE) is a well-established animal model widely used to study human multiple sclerosis, a chronic demyelination disease in the central nervous system (CNS). Recently, important studies have designated that the signaling axis of GLP-1 and its receptor controls the clinical manifestations and pathogenesis of EAE. However, it is elusive whether GLP-1 receptor signaling regulates the phenotype of autoreactive T cells in the CNS. We administered dulaglutide, a well-established GLP-1 receptor agonist (GLP-1 RA), to treat EAE mice prophylactically or semi-therapeutically and subsequently analyzed the mononuclear cells of the CNS. In this study, dulaglutide treatment significantly alleviates the clinical manifestations and histopathological outcomes of EAE. Dulaglutide decreases incidences of encephalitogenic Th1/Th17 cells and Th1 granulocyte-macrophage-colony-stimulating factor (GM-CSF) expression in the CNS. Administration of dulaglutide failed to control the chemotactic abilities of encephalitogenic Th1 and Th17 cells; however, prophylactic treatment considerably decreased the populations of dendritic cells and macrophages in the CNS parenchyma. These results obtained indicate that dulaglutide modulates the differentiation of encephalitogenic Th1/Th17 and the pathogenicity of Th1 cells by influencing antigen presenting cells quantities, providing mechanism insight on T cells regulation in ameliorating EAE by GLP-1.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In EAE mice, dulaglutide significantly alleviated clinical manifestations.

    In plain wordsIn mice with EAE, dulaglutide reduced clinical signs of the disease.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseClinical manifestations of EAE
    Study

    mousen: not reported in source

    Experimental autoimmune encephalomyelitis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, dulaglutide treatment significantly alleviates the clinical manifestations and histopathological outcomes of EAE.
    1 context sentence
    Summary · context
    We administered dulaglutide, a well-established GLP-1 receptor agonist (GLP-1 RA), to treat EAE mice prophylactically or semi-therapeutically and subsequently analyzed the mononuclear cells of the CNS.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In EAE mice, dulaglutide significantly alleviated histopathological outcomes.

    In plain wordsIn mice with EAE, dulaglutide reduced disease changes seen in tissue examinations.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHistopathological outcomes of EAE
    Study

    mousen: not reported in source

    Experimental autoimmune encephalomyelitis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, dulaglutide treatment significantly alleviates the clinical manifestations and histopathological outcomes of EAE.
    1 context sentence
    Summary · context
    We administered dulaglutide, a well-established GLP-1 receptor agonist (GLP-1 RA), to treat EAE mice prophylactically or semi-therapeutically and subsequently analyzed the mononuclear cells of the CNS.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In EAE mice, dulaglutide decreased the incidence of encephalitogenic Th1/Th17 cells in the CNS.

    In plain wordsIn mice with EAE, dulaglutide reduced disease-associated Th1/Th17 immune cells in the central nervous system.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCNS encephalitogenic Th1/Th17 cell incidence
    Study

    mousen: not reported in source

    Experimental autoimmune encephalomyelitis
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide decreases incidences of encephalitogenic Th1/Th17 cells and Th1 granulocyte-macrophage-colony-stimulating factor (GM-CSF) expression in the CNS.
    1 context sentence
    Summary · context
    We administered dulaglutide, a well-established GLP-1 receptor agonist (GLP-1 RA), to treat EAE mice prophylactically or semi-therapeutically and subsequently analyzed the mononuclear cells of the CNS.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In EAE mice, dulaglutide decreased Th1 GM-CSF expression in the CNS.

    In plain wordsIn mice with EAE, dulaglutide reduced GM-CSF expression by Th1 immune cells in the central nervous system.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTh1 GM-CSF expression
    Study

    mousen: not reported in source

    Experimental autoimmune encephalomyelitis
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide decreases incidences of encephalitogenic Th1/Th17 cells and Th1 granulocyte-macrophage-colony-stimulating factor (GM-CSF) expression in the CNS.
    1 context sentence
    Summary · context
    We administered dulaglutide, a well-established GLP-1 receptor agonist (GLP-1 RA), to treat EAE mice prophylactically or semi-therapeutically and subsequently analyzed the mononuclear cells of the CNS.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In EAE mice, dulaglutide failed to control encephalitogenic Th1 and Th17 cell chemotactic abilities.

    In plain wordsIn mice with EAE, dulaglutide did not control movement toward chemical signals by disease-associated Th1 and Th17 immune cells.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeTh1 and Th17 chemotactic abilities
    Study

    mousen: not reported in source

    Experimental autoimmune encephalomyelitis
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Administration of dulaglutide failed to control the chemotactic abilities of encephalitogenic Th1 and Th17 cells;
    1 context sentence
    Summary · context
    We administered dulaglutide, a well-established GLP-1 receptor agonist (GLP-1 RA), to treat EAE mice prophylactically or semi-therapeutically and subsequently analyzed the mononuclear cells of the CNS.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In EAE mice, prophylactic dulaglutide considerably decreased dendritic cell populations in CNS parenchyma.

    In plain wordsIn mice with EAE, preventive dulaglutide reduced dendritic immune cells in central nervous system tissue.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCNS dendritic cell populations
    Study

    mousen: not reported in source

    Experimental autoimmune encephalomyelitis
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    however, prophylactic treatment considerably decreased the populations of dendritic cells and macrophages in the CNS parenchyma.
    1 context sentence
    Summary · context
    We administered dulaglutide, a well-established GLP-1 receptor agonist (GLP-1 RA), to treat EAE mice prophylactically or semi-therapeutically and subsequently analyzed the mononuclear cells of the CNS.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In EAE mice, prophylactic dulaglutide considerably decreased macrophage populations in CNS parenchyma.

    In plain wordsIn mice with EAE, preventive dulaglutide reduced macrophages in central nervous system tissue.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCNS macrophage populations
    Study

    mousen: not reported in source

    Experimental autoimmune encephalomyelitis
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    however, prophylactic treatment considerably decreased the populations of dendritic cells and macrophages in the CNS parenchyma.
    1 context sentence
    Summary · context
    We administered dulaglutide, a well-established GLP-1 receptor agonist (GLP-1 RA), to treat EAE mice prophylactically or semi-therapeutically and subsequently analyzed the mononuclear cells of the CNS.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.